Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on November 8, 2022. The filing announces the financial results for the quarter ended September 30, 2022. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text. The filing text does not provide a clear value for these metrics.
Material Changes
No specific material changes or comparative financial data versus prior periods are detailed in the provided text. The filing indicates that the full details of the results are contained in the referenced press release.
Guidance, Outlook, and Disclosures
- Regulation FD Disclosure: The Company updated its corporate deck, available on its investor relations website.
- Legal Disclaimer: The information in this report, including the press release, is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 8, 2022) for specific Q3 2022 revenue, net loss, and cash position figures.
- Verify the updated corporate deck on the company's investor website for strategic outlook and pipeline updates.
- Confirm the company's cash runway and burn rate, as these are critical for a pre-revenue or early-stage biotech firm but are not listed in this summary text.